Podcast Episode

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS

Listen Free in iTunes 

Listen Free on Stitcher Radio

Dr. Robert A. Beardsley or “Al” is a Co-Founder and the Chief Operating Officer at Galera Therapeutics, a clinical-stage biotech company discovering and developing innovative cancer treatments. Al received his BS in Chemical Engineering from the University of Iowa, an MBA in finance from the University of Chicago, and subsequently his PhD in Biochemical Engineering from the University of Iowa. Prior to co-founding Galera Therapeutics, Al served as CEO at Metabolic Solutions Development Corporation, CEO of Kereos, acting CEO at Metaphore Pharmaceuticals, and he has held various roles at Confluence Life Sciences, SImile Investors, bioStrategies Group, and Vector Securities International. Galera Therapeutics’ new drug Abasopasem Manganese has been designated as a “Breakthrough Therapy” by the FDA for reduction in the duration, incidence, and severity of oral mucositis induced by radiation therapy in cancer patients. Recently, Al and the team at Galera Therapeutics raised $150 million in investment for their company, which represents the largest single capital round ever raised by a life-sciences company founded in St. Louis. In this podcast interview, Al spoke with us about his experiences in life and science.

[Read more…] about 479: Dr. Robert A. Beardsley: Putting Patients First in Developing Drugs to Transform Radiation Therapy for Cancer

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS

Listen Free in iTunes 

Listen Free on Stitcher Radio

Dr. Chad Orzel is the R. Gordon Gould Associate Professor of Physics at Union College. He is also author of the popular science books How to Teach Physics to Your Dog, How to Teach Relativity to Your Dog, Eureka: Discovering Your Inner Scientist, and the soon-to-be-released book Breakfast with Einstein: The Exotic Physics of Everyday Objects. In addition, Chad regularly contributes blog articles for Forbes Magazine. He received his B.A. in Physics from Williams College and his Ph.D. in Chemical Physics from the University of Maryland. Before joining the faculty at Union College, Chad conducted postdoctoral research in the Physics Department at Yale University. In our interview, Chad shared his experiences from his life and science.

[Read more…] about 478: Dr. Chad Orzel: Illuminating the Quantum Physics of Ultracold Atoms

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS

Listen Free in iTunes 

Listen Free on Stitcher Radio

Dr. Allison Okamura is a Professor of Mechanical Engineering at Stanford University. She also holds a courtesy appointment in Computer science there. Allison received her B.S. in Mechanical Engineering from the University of California, Berkeley, and she was awarded her M.S. and Ph.D. both in Mechanical Engineering from Stanford University. Before joining the faculty at Stanford University, Allison was Professor and Vice Chair of Mechanical Engineering at Johns Hopkins University. Allison is the recipient of numerous awards and honors, including being elected as a fellow for the Institute of Electrical and Electronics Engineers (IEEE). She has also been awarded the IEEE Technical Committee on Haptics Early Career Award, the IEEE Robotics and Automation Society Early Academic Career Award, and an NSF CAREER Award. In addition, Allison was honored as a Duca Family University Fellow in Undergraduate Education, a Robert Bosch Faculty Scholar, a Gabilan Fellow, and an Alumni Distinguished Scholar by Stanford University, as well as a Decker Faculty Scholar by Johns Hopkins University. In our interview, Allison speaks more about her experiences in life and science.

[Read more…] about 477: Dr. Allison Okamura: Researching Soft Robots, Medical Robots, and Haptics in Human-Robot Interactions

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS

Listen Free in iTunes 

Listen Free on Stitcher Radio

Dr. Mario Thevis is Vice President of Research, Professor, and head of the Centre for Preventive Doping Research at the German Sport University of Cologne. He is also Director of the European Monitoring Center for Emerging Doping Agents (EuMoCEDA), a forensic chemist, Editor and Chief of the journal Drug Testing and Analysis, and a Research Scientist with the Partnership for Clean Competition. He received his undergraduate education in organic chemistry from RWTH Aachen University as well as in sports sciences from the German Sport University of Cologne. Mario went on to earn his PhD in biochemistry from the German Sport University of Cologne. Afterwards, Mario conducted postdoctoral research at the University of California, Los Angeles. He served as a senior researcher at the German Sport University Cologne for a few years before being appointed Professor for Preventive Doping Research there. In our interview Mario will tell us more about his life and science.

[Read more…] about 476: Dr. Mario Thevis: Developing Methods to Detect and Deter Use of Performance-Enhancing Substances in Sport

Podcast: Play in new window | Download

Subscribe: Apple Podcasts | RSS

Listen Free in iTunes 

Listen Free on Stitcher Radio

Dr. Dennis Riley is Co-Founder and Chief Scientific Officer at Galera Therapeutics, a clinical-stage biotech company discovering and developing innovative cancer treatments. He is also an Adjunct Professor of Chemistry at Washington University in St. Louis. He earned his Bachelor’s degree in chemistry and mathematics from Heidelberg College and his PhD in inorganic chemistry from The Ohio State University. Afterwards, Dennis conducted postdoctoral research at the University of Chicago. Dennis began his career working in research and development with Proctor and Gamble, and he spent much of his career working at Monsanto where he held the positions of Senior Science Fellow and Manager of Metal-Mediated Chemistry. He subsequently served as Vice President of Research at Metaphore Pharmaceuticals and Senior Vice-President at the start-up company Kereos before co-Founding Galera Therapeutics. Dennis is an elected Fellow of the American Association for the Advancement of Science and he has received the American Chemical Society St. Louis Section’s Chemist of the Year Award. In addition, Galera Therapeutics’ new drug GC4419 has been designated as a “Breakthrough Therapy” by the FDA for reduction in the duration, incidence, and severity of oral mucositis induced by radiation therapy in cancer patients. In this podcast interview, Dennis spoke with us about his experiences in life and science.

[Read more…] about 475: Dr. Dennis Riley: Designing Drugs to Decrease Damage in Healthy Tissue During Radiation Therapy Cancer Treatments